Litigation Details for CELGENE CORPORATION v. AUROBINDO PHARMA LIMITED (D.N.J. 2020)

CELGENE CORPORATION v. AUROBINDO PHARMA LIMITED (D.N.J. 2020)

Docket	2:20-cv-02606	Date Filed	2020-03-10
Court	District Court, D. New Jersey	Date Terminated	2020-04-27
Cause	15:1126 Patent Infringement	Assigned To	Esther Salas
Jury Demand	None	Referred To	Michael A. Hammer
Parties	AUROBINDO PHARMA LIMITED
Patents	10,555,939; 6,045,501; 6,561,976; 8,198,262; 8,204,763; 8,828,427; 9,993,467
Link to Docket	External link to docket

Details for CELGENE CORPORATION v. AUROBINDO PHARMA LIMITED (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-10				External link to document

Celgene Corporation v. Aurobindo Pharma Limited, 2:20-cv-02606: Litigation Summary and Patent Analysis

Last updated: September 1, 2026

Celgene Corporation v. Aurobindo Pharma Limited, No. 2:20-cv-02606, was an Abbreviated New Drug Application patent case in the U.S. District Court for the District of New Jersey concerning generic apremilast, the active ingredient in Celgene’s Otezla product. Celgene alleged that Aurobindo’s ANDA filing infringed Otezla patents under 35 U.S.C. § 271(e)(2). The case was resolved without a merits judgment, and the publicly available docket does not disclose the commercial terms of the parties’ resolution. The proceeding created no judicial ruling invalidating the asserted Otezla patents and no public adjudication of non-infringement.

What drug and ANDA were at issue in Celgene v. Aurobindo?

The case concerned apremilast tablets, the generic equivalent of Otezla. Otezla is an oral phosphodiesterase-4 inhibitor approved for several inflammatory conditions, including:

• Psoriatic arthritis
• Plaque psoriasis
• Oral ulcers associated with Behçet’s disease

Celgene was the original sponsor and patent holder associated with Otezla. Bristol Myers Squibb acquired Celgene in 2019, after which BMS became the parent company controlling Celgene’s pharmaceutical assets. The case caption continued to identify Celgene as the plaintiff.

Aurobindo filed an ANDA seeking FDA approval to market generic apremilast tablets. The ANDA included Paragraph IV certifications challenging one or more patents listed in the FDA’s Orange Book for Otezla. A Paragraph IV certification states that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. [1]

Case identification

Item	Detail
Case	Celgene Corporation v. Aurobindo Pharma Limited
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:20-cv-02606
Statutory basis	35 U.S.C. § 271(e)(2)
Plaintiff	Celgene Corporation
Defendant	Aurobindo Pharma Limited
Product	Generic apremilast tablets
Reference product	Otezla
Regulatory pathway	ANDA
Litigation type	Hatch-Waxman patent litigation

What patents protect Otezla and generic apremilast?

Otezla’s patent estate has included compound, formulation, composition, and method-of-use patents. The patents relevant to an ANDA case depend on the Orange Book listings in effect when the ANDA was filed and on the specific certifications made by the applicant.

Publicly reported Otezla patent listings have included the following U.S. patents:

Patent	General subject matter	Reported term profile
U.S. Patent No. 6,962,940	Apremilast compound and related chemical subject matter	Earlier-expiring foundational patent
U.S. Patent No. 8,193,211	Apremilast compositions and pharmaceutical applications	Expiration generally reported in 2028
U.S. Patent No. 8,618,075	Apremilast formulations or related composition claims	Expiration generally reported in 2028
U.S. Patent No. 9,359,356	Otezla-related pharmaceutical composition claims	Expiration generally reported in 2028
U.S. Patent No. 9,630,923	Apremilast composition or use claims	Expiration generally reported in 2028
U.S. Patent No. 10,022,351	Later-issued Otezla-related claims	Later expiration, subject to applicable patent-term calculations
U.S. Patent No. 10,292,922	Later-issued formulation or use claims	Later expiration, subject to Orange Book status

The operative asserted-patent list must be distinguished from the broader Otezla Orange Book portfolio. A complaint may assert only a subset of listed patents, while later-issued patents may not have been relevant to the original ANDA litigation.

How strong was the Otezla patent estate?

The estate had meaningful blocking value because it combined an earlier compound patent with later patents covering formulations, compositions, and therapeutic uses. The earlier compound protection did not represent the entire commercial barrier. Later patents could continue to support litigation after expiration of the foundational patent if the generic applicant’s proposed label, dosage form, or formulation fell within their claims.

The principal weakness was timing. A generic applicant could challenge the later patents years before their expected expiration, forcing the brand company to prove infringement and defend validity. Settlement therefore could preserve commercial exclusivity without requiring Celgene or BMS to litigate every patent through trial.

What were Celgene’s infringement allegations?

Celgene’s complaint was based on Aurobindo’s ANDA filing. In Hatch-Waxman litigation, the ANDA submission itself is treated as an artificial act of infringement for purposes of determining whether the listed patents would be infringed by the proposed commercial product.

Celgene’s allegations would have focused on the following categories:

1. Apremilast composition claims. Celgene could allege that Aurobindo’s proposed tablets contained apremilast in a claimed pharmaceutical composition.

2. Formulation claims. The complaint could target excipient combinations, dosage strengths, release characteristics, or tablet formulations disclosed in the ANDA.

3. Method-of-use claims. If Aurobindo’s proposed label included indications covered by method patents, Celgene could allege induced infringement or infringement based on the ANDA labeling.

4. Patent-term and approval restrictions. Celgene sought an order preventing FDA approval of Aurobindo’s ANDA until the relevant patents expired or the court entered judgment.

The public resolution did not establish whether Aurobindo’s proposed product would have infringed any asserted claim. There was no reported claim-construction ruling, validity decision, or trial verdict in the action.

When did the 30-month stay begin, and what did it mean?

Celgene’s lawsuit triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), assuming the statutory requirements were satisfied. The stay generally prevents FDA approval of the ANDA for up to 30 months from the date the brand company received notice of the Paragraph IV certification.

The stay can end earlier if:

• The court enters a final judgment that the patent is invalid or not infringed;
• The court orders an earlier termination;
• The listed patent expires; or
• The parties resolve the case and the statutory conditions for approval are otherwise satisfied.

The stay is separate from the patent’s substantive expiration date. A settlement can establish a contractual launch date, but the FDA cannot approve an ANDA in violation of an unexpired, enforceable patent injunction or other applicable regulatory restriction.

What was the litigation status and outcome?

The case did not produce a public merits decision. The docket reflects resolution of the dispute rather than a litigated judgment determining that the Otezla patents were valid and infringed or invalid and not infringed.

The practical characterization is:

Issue	Outcome
Infringement trial	No public trial judgment
Patent validity ruling	None publicly reported
Claim-construction ruling	None publicly reported
FDA approval injunction	No merits-based permanent injunction publicly reported
Settlement	Case resolved pursuant to agreement
Settlement terms	Not publicly disclosed in the court record
Commercial entry date	Not publicly disclosed in the docket
Biosimilar issue	Not applicable

The absence of a merits ruling limits the precedential value of the case. It does not invalidate the Otezla patents, confirm their validity, or establish the scope of any asserted claim.

Did Celgene and Aurobindo enter a patent settlement?

The litigation was resolved through a settlement or other agreed disposition. The public docket does not provide the principal economic terms, including:

• Aurobindo’s authorized or licensed launch date;
• Any royalty or supply arrangement;
• Whether Aurobindo received a license to all or only selected patents;
• Whether the agreement included acceleration, forfeiture, or contingent-entry provisions;
• Whether the settlement included a no-challenge covenant;
• Whether Aurobindo was eligible for an authorized-generic arrangement.

Because the terms were not publicly disclosed, the case cannot support a reliable estimate of Aurobindo’s launch timing or the precise scope of the license.

The settlement also should not be treated as evidence that the asserted patents were weak. Brand companies settle cases for reasons that include litigation cost, launch-risk management, market forecasting, regulatory timing, and preservation of patent rights.

What is the Orange Book status of Otezla?

Otezla’s Orange Book status depends on the FDA edition and the specific dosage form or strength reviewed. FDA Orange Book listings identify patents and regulatory exclusivities that may affect ANDA approval. They do not disclose the full terms of confidential patent settlements. [1]

For apremilast, the relevant Orange Book analysis requires review of:

• The listed Otezla patents in effect on the ANDA filing date;
• The certification made for each patent;
• Pediatric exclusivity, if applicable;
• Patent-term adjustments;
• Any expiration-date corrections;
• Whether later-issued patents were added after the original litigation;
• Whether the generic label carved out patented indications.

The Orange Book is a regulatory listing, not a judicial determination that every listed patent is valid or infringed.

What generic entry risks existed for Aurobindo?

Aurobindo faced four principal risks.

Regulatory delay

The Paragraph IV litigation could delay FDA approval through the 30-month stay. The delay could remain commercially important even if the earliest patent had expired, because later-listed patents could affect approval or require a revised certification.

Formulation infringement

Aurobindo could avoid some method-of-use exposure through a section viii labeling carve-out, but formulation and composition claims generally cannot be avoided by removing an indication from the label.

Settlement restrictions

A confidential settlement could impose a fixed launch date or other restrictions. Without the agreement, the market cannot determine whether Aurobindo received an early-entry license or a date close to patent expiry.

Market-entry economics

Apremilast is a small-molecule product, so biosimilar approval risk did not apply. Generic entry would instead depend on ANDA approval, patent clearance, manufacturing readiness, supply capacity, and the number of other generic applicants entering at the same time.

How did this case compare with biosimilar litigation?

The case was not a biosimilar case. Apremilast is a chemically synthesized small molecule regulated through the ANDA pathway. The relevant framework was Hatch-Waxman, including Paragraph IV certifications and the 30-month stay.

Biosimilar litigation under the Biologics Price Competition and Innovation Act involves a different regulatory pathway, including:

• A biologics license application rather than an ANDA;
• Patent-information exchanges under the BPCIA;
• Reference-product exclusivity periods;
• Interchangeability considerations;
• Complex manufacturing and analytical comparability issues.

No biosimilar could directly substitute for generic apremilast under the Otezla ANDA framework.

What commercial exposure did Otezla patent litigation create?

Otezla was a significant commercial asset for Celgene and later BMS. Patent resolution affected the duration of branded pricing, the timing of generic erosion, and the value of the product portfolio following BMS’s acquisition of Celgene.

The case-specific revenue exposure cannot be calculated from the docket because the settlement did not disclose a launch date or financial terms. The main commercial variables were:

• Otezla net sales before generic entry;
• Number of approved generic competitors;
• Aurobindo’s manufacturing scale;
• Generic discounting;
• Pharmacy-benefit-manager substitution;
• Whether entry occurred through an authorized generic or an independent ANDA;
• The extent of remaining patent protection after settlement.

A settlement that permits entry before the latest patent expiry can materially reduce branded revenue even if the brand retains a period of market exclusivity. Conversely, a late-entry settlement can preserve most of the value of the remaining patent term while eliminating trial risk.

Key Takeaways

• Celgene v. Aurobindo, No. 2:20-cv-02606, was a Hatch-Waxman case involving generic apremilast, the active ingredient in Otezla.
• Celgene relied on Otezla-related Orange Book patents and challenged Aurobindo’s Paragraph IV ANDA filing.
• The case ended without a public trial verdict or ruling on patent validity, infringement, or claim construction.
• The parties’ resolution did not publicly disclose Aurobindo’s launch date, royalty obligations, or license scope.
• The dispute involved a small-molecule generic, not a biosimilar.
• The Otezla patent estate included later composition, formulation, and method-related protection beyond the earliest apremilast patent.
• The settlement limits the case’s precedential value but may have controlled Aurobindo’s commercial entry timing.

FAQs About Celgene v. Aurobindo and Otezla Generic Entry

Was Aurobindo the first company to challenge Otezla patents?

The case record alone does not establish that Aurobindo was the first Paragraph IV filer. First-filer status depends on the timing and completeness of ANDA submissions by all competing applicants.

Did Aurobindo receive FDA approval for generic apremilast?

The litigation docket does not establish the date or status of any FDA approval resulting from Aurobindo’s ANDA. Approval status must be evaluated against current FDA ANDA records.

Did Celgene win the case?

Celgene did not obtain a public merits judgment. The case was resolved without a disclosed decision finding infringement or validating the asserted patents.

Could Aurobindo launch before every Otezla patent expired?

Only if the settlement or applicable regulatory and patent conditions permitted that launch. The public docket does not disclose the contractual launch date.

Are Otezla patent settlements reported to the Federal Trade Commission?

Brand-generic patent settlements may be subject to federal reporting requirements. A reported agreement may provide more detail than the district-court docket, but reporting does not necessarily disclose every commercial term.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. U.S. District Court for the District of New Jersey. (2020). Celgene Corporation v. Aurobindo Pharma Limited, No. 2:20-cv-02606, docket records.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
4. U.S. Congress. (2011). Leahy-Smith America Invents Act, 35 U.S.C. § 271(e)(2).
5. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources.